CN107831128A - 尼扎替丁的含量测定方法 - Google Patents
尼扎替丁的含量测定方法 Download PDFInfo
- Publication number
- CN107831128A CN107831128A CN201710911131.9A CN201710911131A CN107831128A CN 107831128 A CN107831128 A CN 107831128A CN 201710911131 A CN201710911131 A CN 201710911131A CN 107831128 A CN107831128 A CN 107831128A
- Authority
- CN
- China
- Prior art keywords
- nizatidine
- acetonitrile
- solution
- content
- chloranilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 title claims abstract description 74
- 229960004872 nizatidine Drugs 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 90
- 239000000243 solution Substances 0.000 claims description 23
- IPPWILKGXFOXHO-UHFFFAOYSA-N chloranilic acid Chemical compound OC1=C(Cl)C(=O)C(O)=C(Cl)C1=O IPPWILKGXFOXHO-UHFFFAOYSA-N 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 7
- 239000012895 dilution Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000012488 sample solution Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000003595 spectral effect Effects 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 6
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract description 6
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract description 6
- 238000011084 recovery Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 238000002798 spectrophotometry method Methods 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 238000002835 absorbance Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000006276 transfer reaction Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AQZMINLSVARCSL-UHFFFAOYSA-N 4-chloro-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile Chemical class ClC1=CC(=O)C(C#N)=C(C#N)C1=O AQZMINLSVARCSL-UHFFFAOYSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- -1 methyl mercapto Chemical compound 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 2
- NLDYACGHTUPAQU-UHFFFAOYSA-N tetracyanoethylene Chemical compound N#CC(C#N)=C(C#N)C#N NLDYACGHTUPAQU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
Landscapes
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开了一种尼扎替丁的含量测定方法。本发明采用荷移分光光度法测定波长通常在可见光区,消除了紫外吸收物质带来的干扰这一优点,另外,此方法还有很多优点:无需昂贵精密仪器、方法简单快速,具有较高灵敏度,能够实现对尼扎替丁含量的快速、准确、高重现性、高回收率的测定,操作简单快捷,适于应用推广,对控制尼扎替丁制剂的质量和保证临床疗效具有重要意义。
Description
技术领域
本发明涉及化学技术领域,具体为一种尼扎替丁的含量测定方法。
背景技术
尼扎替丁分散片、胶囊剂、咀嚼片剂主要成分为尼扎替丁,化学名称为:N-[2-[[2-(二甲胺基甲基)-4-噻唑基]甲硫基]乙基]-N'(-甲基-2-硝基-1,1-乙烯二胺,分子式为C12H21N5O2S2,是一种强效H2受体拮抗药,通过阻滞胃粘膜壁细胞组胺H2受体而发挥作用,对治疗活动性十二指肠溃疡和良性溃疡是一种安全、有效的药物。尼扎替丁于1987年在美国上市,商品名爱希。
发明内容
针对现有技术的不足,本发明提供了一种尼扎替丁的含量测定方法,它测定准确,重现性好,操作简单、分析速度快。
为实现以上目的,本发明通过以下技术方案予以实现:尼扎替丁的含量测定方法,包括以下步骤:
1)尼扎替丁标准溶液的配制:将尼扎替丁标准品用乙腈溶解,定容得到浓度为1.0mg/ml的尼扎替丁溶液,在4℃下保存备用;使用时用乙腈逐级稀释;
2)氯冉酸溶液配制:取氯冉酸用乙腈溶解,定容得到浓度为1.0mg/mL的氯冉酸溶液,现配现用;
3)尼扎替丁样品溶液的制备:取尼扎替丁样品,研碎后,准确称取一定量的样品,用乙腈将尼扎替丁全部溶解后,过滤,滤液置于容量瓶中,滤纸用乙腈洗涤2~3次,合并滤液与洗液,用乙腈稀释到刻度,得到尼扎替丁的供试品溶液;
4)尼扎替丁测定:移取一定量的尼扎替丁溶液于5mL比色管中,加入1.0mg/mL氯冉酸溶液0.2~2.0mL,用乙腈稀释定容,摇匀,室温反应0~90min,以试剂空白为参比,用紫外-可见分光光度计在350~600nm范围内进行光谱扫描,确定络合物的最大吸收波长为516-520nm,从而测定尼扎替丁的含量。
有益效果
本发明提供了一种尼扎替丁的含量测定方法。具备以下有益效果:本发明采用荷移分光光度法测定波长通常在可见光区,消除了紫外吸收物质带来的干扰这一优点,另外,此方法还有很多优点:无需昂贵精密仪器、方法简单快速,具有较高灵敏度,能够实现对尼扎替丁含量的快速、准确、高重现性、高回收率的测定,操作简单快捷,适于应用推广,对控制尼扎替丁制剂的质量和保证临床疗效具有重要意义。
附图说明
图1为本发明的尼扎替丁、氯冉酸(pCA)、尼扎替丁和pCA反应液的紫外-可见吸收光谱图;
图1中a-尼扎替丁、b-氯冉酸(pCA)、c-100ug/mL的尼扎替丁和氯冉酸的反应液、d-150ug/mL的尼扎替丁和氯冉酸的反应液;
图2为不同溶剂对尼扎替丁-氯冉酸络合物形成的影响;
图3为不同表面活性剂对荷移反应的影响;
图4为氯冉酸用量对荷移反应的影响;
图5为反应时间对荷移络合物的影响;
图6为反应温度对荷移反应的影响;
图7为本发明的尼扎替丁与不同电子受体反应后的颜色变化;
图7中尼扎替丁(NIZ)、茜素红(AZR)、四氰基乙烯(TCNE)、茜素(AZ)、氯冉酸(pCA)、2,3-二氯-5,6-二氰基对苯醌(DDQ);
图8为本发明的尼扎替丁与不同浓度pCA反应后的颜色变化;
图9为本发明的尼扎替丁-pCA络合物的标准曲线。
具体实施方式
本发明的实施例:尼扎替丁的含量测定方法,包括以下步骤:
1)尼扎替丁标准溶液的配制:精密称取尼扎替丁标准品25.0mg于烧杯中,用适量乙腈溶解,然后定容到25mL的容量瓶中,浓度为1.0mg/ml,于4℃冰箱保存备用;使用时用乙腈逐级稀释;
2)氯冉酸溶液配制:精密称取氯冉酸50.0mg于烧杯中,用适量乙腈溶解,定容到50mL的容量瓶中,浓度为1.0mg/mL,现配现用;
3)尼扎替丁样品溶液的制备:取尼扎替丁分散片20片(标示量为0.15g/片)内容物,研碎,准确称取相当于尼扎替丁45.0mg的量,用乙腈使尼扎替丁全部溶解后,过滤,滤纸用乙腈溶液洗2~3次,合并滤液与洗液,置100mL量瓶中,用乙腈稀释至刻度,得约0.45mg/mL尼扎替丁乙腈溶液;
4)尼扎替丁测定:移取一定量的尼扎替丁溶液于5mL比色管中,加入1mg/mLpCA溶液0.2~2mL,用乙腈稀释至5mL刻度,摇匀,于室温反应0~90min,以试剂空白为参比,用紫外-可见分光光度计在350~600nm范围内扫描进行光谱扫描,确定络合物的最大吸收波长518nm,从而测定尼扎替丁的含量。
为了进一步验证本发明的技术方案,申请人进行了如下方案:
荷移分光光度法测定尼扎替丁的含量荷移反应条件的选择。
测定波长的选择:按实验方法以试剂空白为参比,在350-600nm范围内进行光谱扫描,绘制吸收光谱,见附图1。由附图1可知:尼扎替丁(曲线a)350-600nm范围内没有明显的吸收峰;氯冉酸(pCA)(曲线b)的最大吸收峰为432nm;加入尼扎替丁后(曲线c)在518nm处出现新的吸收峰,最大吸收峰发生红移至518nm,所以本实验选取518nm作为测定波长。
溶剂的选择:试验考察了甲醇、乙醇、水、二甲亚砜、乙腈、二氯甲烷、1-正丙醇以及95%乙醇常用溶剂对吸光度的影响,结果表明:在相同条件下,当溶剂为水和二甲亚砜时,氯冉酸和水、二甲亚砜发生反应,当溶剂为乙腈时,体系的吸光度最大。试验选择乙腈作为溶剂,结果见附图2。
表面活性剂的影响:按照试验方法,选用十六烷基硫酸钠(SDS)、十六烷基三甲基溴化铵(CTMAB)、乳化剂(OP)、吐温-80、聚氧乙烯蓖麻油(EL-40)、氧化蓖麻油聚氧乙烯醚(RH-40)作为表面活性剂,考察表面活性剂对体系吸光度的影响。结果表明,表面活性剂对反应体系的吸光度没有促进作用,结果见附图3。
氯冉酸用量的影响:在其他条件不变的情况下,固定尼扎替丁的质量浓度为0.6mg/mL,试验考察了1.0mg/mL氯冉酸溶液的用量对测定的影响,结果表明,当氯冉酸的用量为1.0mL时,体系的吸光度最大,随着氯冉酸用量的增加,吸光度反而下降。试验选择氯冉酸的用量为1.0mL,结果见附图4。
反应时间的影响:试验考察了反应时间在0~90min范围内对吸光度的影响,结果表明:当反应时间为10min时,体系吸光度最大,且90min内吸光度无明显变化,试验选择反应时间为10min,结果见附图5。
温度的影响:试验考察了20、25、30、35、40、45、50℃时吸光度的变化。结果表明:不同温度下的吸光度变化不明显。因此,试验选择反应在室温下进行,结果见附图6.
尼扎替丁的含量测定方法的方法学考察
线性关系考察:
在最优反应条件下,对尼扎替丁质量浓度为16.0、32.0、48.0、64.0、80.0、120.0、160.0、200.0、240.0ug/mL的系列工作溶液进行测定,绘制体系的标准曲线,结果表明,尼扎替丁的质量浓度在16.0~240.0ug/mL范围内与吸光度A呈良好的线性关系,其线性回归方程为A=0.0039c+0.01898,相关系数r=0.9997。
检测限和定量限:
基于响应值的标准偏差和标准曲线斜率法计算。按照LOD=3.3δ/S,LOQ=10δ/S(δ是截距的标准偏差,S是标准曲线的斜率)计算,得到其检测限和定量限为3.22和9.77ug/mL。
重复性:
按本发明的实施例所述的含量测定方法制备6份尼扎替丁分散片供试品溶液,再按照步骤4)进行检测,计算得尼扎替丁分散片的标示量为99.55%,RSD=0.62%,(n=6),说明该方法的重复性良好。
干扰物影响
在本发明的最佳条件下,考察了常见辅料以及一些无机离子存在对荷移反应的影响,确定了这些物质无干扰时的最大存在倍数,结果见表1.当尼扎替丁浓度为176.5ug/mL,相对误差在±5%范围内,淀粉、葡萄糖、乳糖等大量存在也不会对测定有影响。
表1共存物质对荷移反应的影响
耐用性:
取尼扎替丁分散片20(标示量0.15g/片)片,精密称定,研细,精密称取93.0mg至烧杯中,用适量乙腈溶解,滤过。滤液及洗液置50mL容量瓶中,用乙腈定容,取1.0mL滤液至5mL容量瓶中,微小改变荷移条件,测定其含量。结果见表2,由表2可知,微小改变荷移条件时,对其测定无显著影响。
表2耐用性测定结果
样品含量测定:
取尼扎替丁分散片20片(标示量为0.15g/片)或尼扎替丁胶囊20粒(标示量为0.15g/粒)内容物,研碎,准确称取相当于尼扎替丁45.0mg的量,用乙腈使尼扎替丁全部溶解后,过滤,滤纸用乙腈溶液洗2~3次,合并滤液与洗液,置100mL量瓶中,用乙腈稀释至刻度,得约0.45mg/mL尼扎替丁乙腈溶液。取2种样品溶液各1.0mL,按实验方法,分别测定2种药物中尼扎替丁的标示百分含量,并与高效液相色谱法测得的标示百分含量结果相比较,结果见表3。
表3尼扎替丁制剂中含量测定结果(n=5)
回收率实验:
分别取2种已测知含量的尼扎替丁样品溶液1mL至5.0mL比色管中,精密加入相当于尼扎替丁含量80%、100%、120%对照品溶液,按本发明步骤(3)的测定方法进行回收试验,结果见表4。由表4可知,本法的准确度较高,数据可靠,可用于药物制剂中尼扎替丁含量的测定。
表4尼扎替丁制剂样品回收率
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (1)
1.一种尼扎替丁的含量测定方法,其特征在于:包括以下步骤:
1)尼扎替丁标准溶液的配制:将尼扎替丁标准品用乙腈溶解,定容得到浓度为1.0mg/ml的尼扎替丁溶液,在4℃下保存备用;使用时用乙腈逐级稀释;
2)氯冉酸溶液配制:取氯冉酸用乙腈溶解,定容得到浓度为1.0mg/mL的氯冉酸溶液,现配现用;
3)尼扎替丁样品溶液的制备:取尼扎替丁样品,研碎后,称取一定量的的样品,用乙腈将尼扎替丁全部溶解后,过滤,滤液置于容量瓶中,滤纸用乙腈洗涤2~3次,合并滤液与洗液,用乙腈稀释到刻度,得到尼扎替丁的供试品溶液;
4)尼扎替丁测定:移取一定量的尼扎替丁溶液于5mL比色管中,加入1.0mg/mL氯冉酸溶液0.2~2.0mL,用乙腈稀释定容,摇匀,室温反应0~90min,以试剂空白为参比,用紫外-可见分光光度计在350~600nm范围内进行光谱扫描,确定络合物的最大吸收波长为516-520nm,从而测定尼扎替丁的含量。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710911131.9A CN107831128A (zh) | 2017-09-29 | 2017-09-29 | 尼扎替丁的含量测定方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710911131.9A CN107831128A (zh) | 2017-09-29 | 2017-09-29 | 尼扎替丁的含量测定方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107831128A true CN107831128A (zh) | 2018-03-23 |
Family
ID=61647644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710911131.9A Pending CN107831128A (zh) | 2017-09-29 | 2017-09-29 | 尼扎替丁的含量测定方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107831128A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109164055A (zh) * | 2018-09-25 | 2019-01-08 | 遵义医学院 | 一种盐酸雷尼替丁的含量测定方法 |
-
2017
- 2017-09-29 CN CN201710911131.9A patent/CN107831128A/zh active Pending
Non-Patent Citations (4)
Title |
---|
KARI M. MORRISSEY ET AL.: "The Effect of Nizatidine, a MATE2K Selective Inhibitor,on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers", 《CLIN PHARMACOKINET》 * |
宣春生等: "西咪替丁与氯醌酸荷移反应的研究", 《光谱实验室》 * |
赵辉等: "荷移分光光度法研究进展", 《化学试剂》 * |
邱月琴等: "荧光探针测定雷尼替丁、尼扎替丁和西咪替丁", 《药物分析杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109164055A (zh) * | 2018-09-25 | 2019-01-08 | 遵义医学院 | 一种盐酸雷尼替丁的含量测定方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Omar et al. | Validated spectrofluorimetric method for determination of selected aminoglycosides | |
CN106706785B (zh) | 一种采用高效液相色谱检测厄贝沙坦氢氯噻嗪片中有关物质的方法 | |
Dhumal et al. | Quantitative determination of moxifloxacin hydrochloride in bulk and ophthalmic solution by UV-spectrophotometry and first order derivative using area under curve | |
CN101915760A (zh) | 一种比色法即时检测半胱氨酸含量的方法 | |
CN111551651B (zh) | 缬沙坦药物组合物中杂质k的检测方法 | |
Hamad | A green fluorescence turn-off system for meclofenoxate determination by Cilefa Pink B dye | |
Singh et al. | Method for determination of tinidazole using direct UV-visible spectrophotometry and differential spectrophotometry in pure and tablet dosage forms | |
CN107831128A (zh) | 尼扎替丁的含量测定方法 | |
Li et al. | Resonance Rayleigh scattering and resonance nonlinear scattering methods for the determination of nicardipine hydrochloride using eosin Y as a probe | |
Gurupadayya et al. | Spectrophotometric determination of meloxicam by sodium nitroprusside and 1, 10-phenanthroline reagents in bulk and its pharmaceutical formulation | |
Ansari et al. | Derivative spectrophotometric method for determination of losartan in pharmaceutical formulations | |
Basavaiah et al. | Determination of tinidazole by potentiometry, spectrophotometry and high performance liquid chromatography | |
Darwish et al. | A sensitive spectrophotometric method for the determination of H-receptor antagonists by means of-bromosuccinimide and-aminophenol | |
CN110927091A (zh) | 一种哌嗪水溶液定量检测的方法 | |
Pulgarín et al. | Direct determination of amiloride in urine using isopotential fluorimetry | |
CN106053367A (zh) | 一种提高化妆品中甲醛含量检测的稳定性和灵敏度的方法 | |
Afkhami et al. | Spectrophotometric Determination of Salicylamide and Paracetamol in Biological Samples and Pharmaceutical Formulations by a Differential Kinetic Method. | |
Mohamed et al. | Spectrofluorimetric determination of certain biologically active phenothiazines in commercial dosage forms and human plasma | |
Sloka et al. | Simultaneous spectrophotometric determination of Naproxen and Pantoprazole in pharmaceutical dosage form | |
Rahman et al. | Initial-rate method for the determination of pantoprazole in pharmaceutical formulations using 1-fluoro 2, 4-dinitrobenzene | |
Basavaiah et al. | Optimized and validated spectrophotometric methods for the determination of raloxifene in pharmaceuticals using permanganate | |
EP3692366B1 (en) | Selective optical aqueous and non-aqueous detection of free sulfites | |
Elbashir et al. | Spectrophotometric determination of ranitidine hydrochloride (RNH) in pharmaceutical formulation using 9-fluorenylmethyl chloroformate (FMOC-Cl) | |
Satyanarayana et al. | Simple and facile spectrophotometric methods for the determination of amisulpride in pharmaceutical formulations | |
Elgailani et al. | Spectrophotometric Determination of Some Antiulcerative Drugs in Pharmaceutical Dosages |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180323 |
|
RJ01 | Rejection of invention patent application after publication |